Vascular and metabolic effects of methylprednisolone and phenoxybenzamine during controlled hypotension in the dog. 1981

U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg

The relationship between central haemodynamics and vascular and metabolic parameters in skeletal muscle was studied in dogs subjected to controlled haemorrhagic hypotension and treated with cumulative doses of methylprednisolone (4-32 mg x kg-1), (or saline in the control group), followed by phenoxybenzamine. There were no significant haemodynamic or metabolic changes between the groups during the injections of steroid or saline. The alpha-adrenergic receptor blockade caused, as found earlier, a pronounced vasodilation in the steroid group, which was parallelled by an increase in muscle blood flow in the same order of magnitude. There was no clearcut relationship between metabolic and vascular effects in the groups. Despite the significant difference in blood flow between the groups after phenoxybenzamine, only small and insignificant differences were seen in muscle metabolites, with the exception of muscle lactate which showed higher values in the steroid group. The study provides further evidence in support of the hypothesis that the haemodynamic effects of the combination of methylprednisolone and phenoxybenzamine are of neurogenic origin.

UI MeSH Term Description Entries
D007023 Hypotension, Controlled Procedure in which arterial blood pressure is intentionally reduced in order to control blood loss during surgery. This procedure is performed either pharmacologically or by pre-surgical removal of blood. Controlled Hypotension,Hypotension, Induced,Induced Hypotension
D007773 Lactates Salts or esters of LACTIC ACID containing the general formula CH3CHOHCOOR.
D008297 Male Males
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D010643 Phenoxybenzamine An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator. Dibenylene,Dibenyline,Dibenziran,Dibenzylin,Dibenzyline,Dibenzyran,Phenoxybenzamine Hydrochloride,Hydrochloride, Phenoxybenzamine
D010725 Phosphocreatine An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996) Creatine Phosphate,Neoton,Phosphocreatine, Disodium Salt,Phosphorylcreatine,Disodium Salt Phosphocreatine,Phosphate, Creatine
D011773 Pyruvates Derivatives of PYRUVIC ACID, including its salts and esters.
D011941 Receptors, Adrenergic Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of G-proteins with which they bind; this scheme does not respect the alpha-beta distinction. Adrenergic Receptors,Adrenoceptor,Adrenoceptors,Norepinephrine Receptor,Receptors, Epinephrine,Receptors, Norepinephrine,Adrenergic Receptor,Epinephrine Receptors,Norepinephrine Receptors,Receptor, Adrenergic,Receptor, Norepinephrine

Related Publications

U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
January 1986, The Journal of pharmacology and experimental therapeutics,
U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
April 1980, Acta anaesthesiologica Scandinavica,
U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
March 1979, Minnesota medicine,
U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
June 1984, Anesthesiology,
U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
March 1966, The American journal of physiology,
U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
March 1979, Surgery, gynecology & obstetrics,
U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
February 1984, Acta anaesthesiologica Scandinavica,
U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
January 1980, Circulatory shock,
U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
January 1972, Acta chirurgica Scandinavica,
U Haglund, and H Haljamäe, and A Hellman, and E Häggendal, and E Jennische, and D Lundberg
January 1976, Acta anaesthesiologica Scandinavica,
Copied contents to your clipboard!